Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
HOME > REGULATORY
REGULATORY
- Health Ministry Panel Calls for Simplified Certification Process for Vaccines to Ensure Stable Supplies
December 27, 2019
- Japan Lays Out Action Plan for Whole Genome Analysis; Preliminary Project to Cover 64,000 Cancer Patients, 28,000 for Intractable Diseases
December 27, 2019
- AMED’s Kono Tapped to Lead Medical Device Review at MHLW
December 26, 2019
- Japan's Global Health Confab to Prepare New Grand Design for Regulatory Harmonization in Asia
December 26, 2019
- MHLW to Establish Clinical Research Centers for Pediatric, Rare Diseases: FY2020 Budget
December 25, 2019
- 930 Million Yen Allocated for Amended PMD Law-Related Projects: MHLW Pharma Safety Bureau
December 24, 2019
- Fumi Yamamoto 1st Woman to Become MHLW’s Top Pharmacy Officer
December 23, 2019
- Govt’s All-Generation Social Security Panel Compiles Interim Report, No Mention of OTC-Like Drugs
December 23, 2019
- Japan OKs FY2020 Budget, Record 35.86 Trillion Yen Allotted to Social Security
December 23, 2019
- Japan Approves Keytruda’s 1st Line RCC, Head and Neck Cancer Use, Bavencio’s Label Expansion and More
December 23, 2019
- MHLW Panel Concerned about Further Clinical Trial for Eisai’s Investigational Epilepsy Drug Following Death
December 23, 2019
- Japan to Shave Drug Spending by 4.38% in FY2020 Price Revision: MHLW
December 20, 2019
- Japan Panel Hammers Out FY2020 Drug Pricing Reform
December 20, 2019
- MHLW Council Holds Off Nonprescription Switches for Domperidone, Menatetrenone
December 20, 2019
- Councilor Mori, MHLW's Top Pharmacy Officer, to Bow Out at Year-End
December 19, 2019
- Japan, China, South Korea Adopt Joint Statement on Prevention and Control of Infectious Diseases
December 19, 2019
- FY2020 Drug Price Revision to Shed 110 Billion Yen in Central Govt Spending
December 18, 2019
- Promotion Guidelines Now in Full Effect, MHLW Starts Survey to Capture Leading Examples of Company Set-Ups
December 17, 2019
- Nobel Laureate Honjo Presses for More AMED Funding for Basic Research
December 17, 2019
- Up-to-5-Band Plan OK’ed for Unreasonable Generic Price Rises, Change to Affect Single Price Band Rule Too
December 16, 2019
ページ
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…